GlassScriptPhysician profile
Ruliang Xu
NPI 1922007665
$674.86
in general payments reported to CMS, 2019-2025
9 companies · $130 in 2025
The $130 reported for 2025 was more than what a typical Anatomic Pathology & Clinical Pathology provider received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $15.10 · 2021: $81.28 · 2023: $173 · 2024: $25.81 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $328.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $150.00 | 2023 | Itind System |
| Alexion Pharmaceuticals, INC. | $130.05 | 2025 | Ultomiris |
| Gilead Sciences, INC. | $125.00 | 2019 | |
| Hologic Sales and Service, LLC | $125.00 | 2019 | |
| Abbott Laboratories | $70.06 | 2021 | |
| Roche Diagnostics Corporation | $25.81 | 2024 | |
| Merck Sharp & Dohme LLC | $22.62 | 2023 | Keytruda |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.10 | 2020 | |
| Endo Pharmaceuticals INC. | $11.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruliang Xu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.